A Multi-Peptide Hybrid LC-MS/MS Assay for the Determination of CTI-1601 in Monkey Tissues Provides Insight into its Disposition and Processing
Click here to view the poster.
Presented at EBF Symposium 2019, authors: Jean-Nicholas Mess1, Kevork Mekhssian1, David Bettoun2, Jennifer Johansson2, Anahita Keyhani1
1 Altasciences, Laval, QC, Canada 2Chondrial Therapeutics, Bala Cynwyd, PA, USA
Friedreich’s Ataxia (FA) is a rare genetic disease caused by a deficiency of the mitochondrial protein Frataxin (FXN). CTI-1601, a 24.9 kDa fusion protein currently under investigation as a protein replacement therapy to restore functional levels of FXN in the mitochondria of FA patients, consists of the cell-penetrating peptide TAT linked to the N-terminus of the full-length human FXN protein. CTI-1601 mechanism of action relies on the cell-penetrating ability of the TAT peptide and the subsequent processing into mature FXN after translocation into the mitochondria. To understand the disposition and processing of CTI-1601, a hybrid LC-MS/MS assay was developed to quantify CTI-1601 in cynomolgus monkey buccal cells, skin biopsies, and platelets. After tissue homogenization and cell lysis, CTI-1601 was immunopurified using an anti-FXN antibody followed by trypsin digestion and LC-MRM analysis. Three peptides were monitored, one from the N-Terminal TAT domain and two from the FXN protein. A full-length SILAC labeled CTI-1601 was used as the internal standard. The assay was qualified for a range of 0.250 to 25.0 ng/mL with accuracy between 80-120% and precision ≤ 20%. The data suggest that, following repeated administration of CTI-1601 for 14 days, CTI-1601 not only accumulates in the tissues outside of the systemic circulation but is also predominantly present as the mature FXN protein. In conclusion, this study exemplifies how hybrid LC-MS/MS assays can be used to simultaneously gain insight into the disposition and processing of biotherapeutics.
Our deep expertise and capabilities in a broad range of therapeutic areas encompasses preclinical and early clinical studies for both small molecules and biologics. We can manage your entire program, as well as provide support research services and bioanalytical expertise.
Please see Therapeutic Areas for a fuller discussion of our capabilities and expertise.